Biotech Values

[mcbio]

Are you saying it's more of a "me-too" drug that may be unable to differentiate itself from approved drugs or those under development?

I believe SNSS claims the drug (Voreloxin) is a first-in class, novel naphthyridine analog (related to quinolones). Voreloxin at least appears to be an active drug and the market cap for the company is under $15 million and I do hold it, so that's why the interest from me.

Thanks